These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 16156677)

  • 81. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R; Ling H
    J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Initiating dopaminergic treatment in Parkinson's disease.
    Lang AE; Marras C
    Lancet; 2014 Sep; 384(9949):1164-6. PubMed ID: 24928806
    [No Abstract]   [Full Text] [Related]  

  • 84. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 86. History of levodopa and dopamine agonists in Parkinson's disease treatment.
    Tolosa E; Martí MJ; Valldeoriola F; Molinuevo JL
    Neurology; 1998 Jun; 50(6 Suppl 6):S2-10; discussion S44-8. PubMed ID: 9633679
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Uncertainties in the pharmacotherapy of Parkinson's disease and how to solve them.
    Overstall PW; Clarke CE
    Gerontology; 2002; 48(1):30-3. PubMed ID: 11844927
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Parkinson's disease severity and use of dopaminergic medications.
    Fang JY; Pérez A; Christine CW; Leehey M; Aminoff MJ; Boyd JT; Morgan JC; Dhall R; Nicholas AP; Bodis-Wollner I; Zweig RM; Goudreau JL;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):297-9. PubMed ID: 25541182
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
    Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
    Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Update on current care guidelines. Parkinson's disease].
    Reijo M; Atula S; Heikkinen E; Jaakkola MR; Pekka J; Keränen T; Martikainen K; Pekkonen E; Sotaniemi K;
    Duodecim; 2010; 126(19):2289-90. PubMed ID: 21086687
    [TBL] [Abstract][Full Text] [Related]  

  • 91. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 92. What is the best initial treatment in Parkinson's disease?
    Sharp ME; Mazzoni P
    J R Coll Physicians Edinb; 2014; 44(4):291-2. PubMed ID: 25516899
    [No Abstract]   [Full Text] [Related]  

  • 93. Guideline for the treatment of Parkinson's disease.
    Carr J; Kies B; Fine J;
    S Afr Med J; 2009 Oct; 99(10):755-6, 758. PubMed ID: 20128276
    [No Abstract]   [Full Text] [Related]  

  • 94. [Are there innovations in the treatment of Parkinson's disease?].
    Ludin HP
    Praxis (Bern 1994); 2004 Nov; 93(45):1865-8. PubMed ID: 15571301
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Parkinson's Disease: A Review from Pathophysiology to Treatment.
    Marino BLB; de Souza LR; Sousa KPA; Ferreira JV; Padilha EC; da Silva CHTP; Taft CA; Hage-Melim LIS
    Mini Rev Med Chem; 2020; 20(9):754-767. PubMed ID: 31686637
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
    Szczudlik A; Rudzińska M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.